FOLH1 and prostate cancer: For future studies, a 24-h interval is proposed using the lower (0.03 mg/kg) OTL78 dose, given the strong retention of OTL78 in PSMA-overexpressing prostate cancer cells and the expected lymphatic clearance of unbound agent.